4.7 Editorial Material

Short or Long-term Osteoporosis Therapy With Denosumab?

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Endocrinology & Metabolism

Risk factors for vertebral fractures and bone loss after denosumab discontinuation: A real-world observational study

J. Everts-Graber et al.

Summary: Patients who received zoledronate after denosumab discontinuation had fewer vertebral fractures, while all subsequent therapies were able to maintain bone mineral density to some extent. Factors such as age, BMI, treatment duration, prior therapy, and BMD gains during denosumab treatment influenced bone mineral density loss, while bone turnover markers correlated with total hip bone loss and treatment duration.
Correction Biochemistry & Molecular Biology

Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption (vol 184, pg 1330, 2021)

Michelle M. McDonald et al.

Article Endocrinology & Metabolism

Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases

Peter Burckhardt et al.

Summary: The risk of vertebral fractures (VFs) after treatment with denosumab (Dmab) is associated with increase in bone resorption markers and bone mineral density during and after treatment. Bisphosphonates, especially after Dmab, have a protective effect against VFs. The risk of VFs is poorly predictable before Dmab prescription, but bone markers and BMD during and after treatment have predictive value.

JOURNAL OF BONE AND MINERAL RESEARCH (2021)

Article Endocrinology & Metabolism

The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation

Polyzois Makras et al.

Summary: The duration of denosumab treatment significantly influences the efficacy of subsequent zoledronate infusion in maintaining bone mineral density gains. Frequent follow-up of patients treated with denosumab for more than 3 years is advisable as additional therapeutic interventions may be necessary.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

Article Endocrinology & Metabolism

Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment

Serge Ferrari et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)